Production of effective, low-cost, and efficient radiopharmaceuticals is an important task and requires further research and clinical studies. In this clinical trial, safety and efficacy of 177Lu/153Sm-ethylenediamine tetramethylene phosphonic acid (EDTMP) cocktail has been evaluated for pain relief of bone metastases.
Materials and Methods:
Twenty-five patients with the mean age of 55.5 ± 15.8 years participated in this study. Patients received a total dose of 37 MBq/kg. Pain and performance assessments were followed using a Brief Pain Inventory form. Complete blood count and renal and liver function tests were also performed up to 12 weeks postadministration.
Results:
Eighteen patients (72%) demonstrated complete pain relief (relief = 100%) and approximately all patients (96%) experienced significant improvement in their quality of life. No grade IV hematological toxicity was observed during the 12-week follow-up period, and grade III toxicity was seen in 1 patient only. In addition, no abnormalities were seen in renal and liver function during the follow-up period.
Conclusions:
There were no considerable complications after administration of 177Lu/153Sm EDTMP; this cocktail seems to be a safe and effective treatment for bone pain palliation in patients with skeletal metastases and improves the quality of life.
Get full access to this article
View all access options for this article.
References
1.
IAEA-TECDOC-1549. Criteria for Palliation of Bone Metastases Clinical Applications. Vienna, Austria: IAEA, 2007.
2.
PapachristouDJ, BasdraEK, PapavassiliouAG. Bone metastases: Molecular mechanisms and novel therapeutic interventions. Med Res Rev, 2012; 32:611.
3.
Pandit-TaskarN, BatrakiM, DivgiCR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med, 2004; 45:1358.
4.
SartorO, ReidRH, BushnellDL, et al.Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer, 2007; 109:637.
5.
RicciS, BoniG, PastinaI, et al.Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging, 2007; 34:1023.
6.
Delgado BoltonRC, GiammarileF. Bone radionuclide therapy and increased survival with radium-223 is the way to go for nuclear medicine: The offer that oncologists cannot refuse. Eur J Nucl Med Mol Imaging, 2018; 45:822.
7.
Handkiewicz-JunakD, PoeppelTD, BodeiL, et al.EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides. Eur J Nucl Med Mol Imaging, 2018; 45:846.
8.
ArunS, AjithJ, RavitejaN, et al.68Ga-PSMA PET/CT imaging and 153Sm-EDTMP bone pain palliation therapy. Clin Nucl Med, 2016; 41:e353.
9.
TapasD, AjitSH, KamaleshwaranK, et al.Theranostic treatment of metastatic bone pain with 177Lu-DOTMP. Clin Nucl Med, 2016; 41:966.
10.
MalliaMB, ShintoAS, KameswaranM, et al.A freeze-dried kit for the preparation of (188)Re-HEDP for bone pain palliation: Preparation and preliminary clinical evaluation. Cancer Biother Radiopharm, 2016; 31:139.
11.
ChakrabortyS, DasT, BanerjeeS, et al.177Lu-EDTMP: A viable bone pain palliative in skeletal metastasis. Cancer Biother Radiopharm, 2008; 23:202.
12.
BrennerW, KampenWU, KampenAM, et al.Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease. J Nucl Med, 2001; 42:230.
13.
AlaviM, OmidvariSh, MehdizadehA, et al.Metastatic bone pain palliation using 177Lu-ethylenediaminetetramethylene phosphonic acid. World J Nucl Med, 2015; 14:109.
14.
ThapaP, NikamD, DasT, et al.Clinical evaluation of efficacy and safety of 177Lu-EDTMP in patients with painful skeletal metastasis: A multiparametric comparison with 153Sm-EDTMP on equidose basis. J Nucl Med, 2015; 56:1513.
15.
CollinsC, EaryJ, DonaldsonG, et al.Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial. J Nucl Med, 1993; 34:1839.
16.
EaryJ, CollinsC, StabinM, et al.Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med, 1993; 34:1031.
17.
BishayeeA, RaoDV, SrivastavaSC, et al.Marrow-sparing effects of 117mSn(4+)diethyle-netriaminepentaacetic acid for radionuclide therapy of bone cancer. J Nucl Med, 2000; 41:2043.
18.
BouchetLG, BolchWE, GodduSM, et al.Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J Nucl Med, 2000; 41:682.
19.
GodduSM, BishayeeA, BouchetLG, et al.Marrow toxicity of 33 P- versus 32P-orthophosphate: Implications of therapy of bone pain and bone metastases. J Nucl Med, 2000; 41:941.
20.
CoronadoM, RedondoA, CoyaJ, et al.Clinical role of Sm-153-EDTMP in the treatment of painful bone metastatic disease. Clin Nucl Med, 2006; 31:605.
21.
AhonenA, JoensuuH, HiltunenJ, et al.Samarium-153-EDTMP in bone metastases. J Nucl Biol Med, 1994; 38:123.
BernhardtP, BenjegårdSA, KölbyL, et al.Dosimetric comparison of radionuclides for therapy of somatostatin receptor-expressing tumors. Int J Radiat Oncol Biol Phys, 2001; 51:514.
24.
SymeAM, KirkbyC, RiaukaTA, et al.Monte Carlo investigation of single cell beta dosimetry for intraperitoneal radionuclide therapy. Phys Med Biol, 2004; 49:1959.
25.
YuanJ, LiuC, LiuX, et al.Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: A phase II study. Clin Nucl Med, 2013; 38:88.
26.
ShintAS, ShibuD, KamaleshwaranKK, et al.177Lu-EDTMP for treatment of bone pain in patients with disseminated skeletal metastases. J Nucl Med Technol, 2014; 42:55.
27.
RanjbarH, Bahrami-SamaniA, BeikiD, et al.Evaluation of 153Sm/177Lu-EDTMP mixture in wild-type rodents as a novel combined palliative treatment of bone pain agent. J Radioanal Nucl Chem, 2015; 303:71.
28.
BijurPE, SilverW, GallagherEJ. Reliability of the visual analog scale for measurement of acute pain. Acad Emerg Med, 2001; 8:1153.
29.
CleelandCS, RyanKM. Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore, 1994; 23:129.
30.
SharmaS, SinghB, KoulA, et al.Deviation in the predefined calibration factors of the dose calibrators and the associated inaccuracy in the radioactivity measurements of beta-gamma emitters. Indian J Nucl Med, 2015; 30:122.
31.
StabinMG. Fundamentals of Nuclear Dosimetry. New York: Springer, 2008.
32.
AgarwalKK, SinglaS, AroraG, et al.(177)Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: A phase II study. Eur J Nucl Med Mol Imaging, 2015; 42:79.
33.
DasT, ChakrabortyS, UnniPR, et al.177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Appl Radiat Isot, 2002; 57:177.
34.
AndoA, AndoI, TonamiN, et al.Lu-177-EDTMP: A potential therapeutic bone agent. Nucl Med Commun, 1998; 19:587.
35.
AyatiN, AryanaK, JalilianA, et al.Treatment efficacy of 153Sm-EDTMP for painful bone metastasis. Asia Oceania J Nucl Med Biol, 2013; 1:27.
36.
BaczykM, CzepczynskiR, MileckiP, et al.89 Sr versus 153Sm-EDTMP: Comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun, 2007; 28:245.
37.
RanjbarH, Bahrami-SamaniA, BeikiD, et al.Development of 153Sm/177Lu-EDTMP as a possible therapeutic complex. Iran J Nucl Med, 2017; 25:11.
38.
LiepeK, KotzerkeJ. A comparative study of 188Re-HEDP,186Re-HEDP,153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun, 2007; 28:623.
